Charles Schwab’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Charles Schwab’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-53,310	Closed	-$1.49M	–	3204
2019 Q3	$1.49M	Sell	53,310 -14,076	-21%	-$228K	﹤0.01%	2472
2019 Q2	$951K	Buy	67,386 +3,992	+6%	+$38K	﹤0.01%	2591
2019 Q1	$564K	Sell	63,394 -5,450	-8%	-$44.2K	﹤0.01%	2721
2018 Q4	$522K	Sell	68,844 -968	-1%	-$15.6K	﹤0.01%	2753
2018 Q3	$1.46M	Buy	69,812 +44,108	+172%	+$1.05M	﹤0.01%	2516
2018 Q2	$770K	Buy	25,704 +12,204	+90%	+$332K	﹤0.01%	2666
2018 Q1	$367K	Buy	13,500 +3,600	+36%	+$108K	﹤0.01%	2816
2017 Q4	$286K	Hold	9,900	–	–	﹤0.01%	2892
2017 Q3	$241K	Buy	+9,900	New	+$235K	﹤0.01%	2951

Charles Schwab's DOVA Position: Q4 2019 in Review

Charles Schwab sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 53,310 shares — an estimated $1.49M sold.

Charles Schwab first reported a position in DOVA in Q3 2017 and held it in 9 quarters. The position peaked at $1.49M in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

Charles Schwab reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Charles Schwab sold 53,310 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $1.49M.
Charles Schwab first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Charles Schwab's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.49M in Q3 2019.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Charles Schwab's 13F filing for Q4 2019, filed 7 Feb 2020.